Σεπ222025ΝέαFeaturedΑνακοινώσεις Δείτε ΕΔΩ το σχετικό ΦΕΚ Κατηγορίες Νέα, , Featured, Ανακοινώσεις22 Σεπτεμβρίου 2025 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real- World Analysis of the IMMUreal CohortΕπόμενοNext post:Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II studyΣχετικά ΆρθραΠερίπτωση ασθενούς (Οκτώβριος 2025)24 Οκτωβρίου 2025Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study23 Οκτωβρίου 2025Risk of de novo HCC in patients with MASLD following direct acting antiviral-induced cure of HCV infection23 Οκτωβρίου 2025Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE20 Οκτωβρίου 2025Navigating second-line therapy after immunotherapy in advanced HCC17 Οκτωβρίου 202519ο Σχολείο Κλινικής Ηπατολογίας :συμμετέχοντες15 Οκτωβρίου 2025
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study23 Οκτωβρίου 2025
Risk of de novo HCC in patients with MASLD following direct acting antiviral-induced cure of HCV infection23 Οκτωβρίου 2025
Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE20 Οκτωβρίου 2025
